Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

British Biotech discontinues development of MMP inhibitor

Dec. 9, 1996

Access in-licenses polymer platinum compounds

Dec. 9, 1996

Bayer reveals sugar-modified cytostatic agents

Dec. 9, 1996

Varian, University of Arizona collaborate on methods of enhancing gene therapy efficacy

Dec. 6, 1996

Antitumor enhancers claimed by Taiho

Dec. 5, 1996

RPR continues research into taxanes

Dec. 5, 1996

Calydon's lead cancer therapeutic progresses toward clinical trials

Dec. 4, 1996

Schering-Plough continues research into FPTase inhibitors

Dec. 4, 1996

EGFR tyrosine kinase inhibitors from Ciba-Geigy for hyperproliferative conditions

Dec. 4, 1996

Enhanced chemotherapeutic efficacy reported for amsalog combination

Dec. 3, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...